Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genelabs raises $23.7 million

GNLB raised $23.7 million in a registered direct offering of 12.9 million units at $1.84 per

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE